Design of potent linear alpha-melanotropin 4-10 analogues modified in positions 5 and 10.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Medicinal Chemistry

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 2535874
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differentiation of the structural features of melanotropins important for biological potency and prolonged activity in vitro.

  2009cited by this paper
• Hormone conjugated with antibody to CD3 mediates cytotoxic T cell lysis of human melanoma cells.

  1988cited by this paper
• alpha-Melanotropin: the minimal active sequence in the frog skin bioassay.

  1987cited by this paper
• Biological activity, binding, and metabolic fate of Ac‐[Nle4, D‐Phe7]α‐MSH4–11NH2 with the F1 variant of B16 melanoma cells

  1987cited by this paper
• Estrogen-linked 2-chloroethylnitrosoureas: anticancer efficacy in MNU-induced rat mammary carcinoma, uterine activity in mice and receptor interactions.

  1986cited by this paper
• Recovery from peripheral nerve transection is accelerated by local application of alpha-MSH by means of microporous Accurel polypropylene tubes.

  1986cited by this paper
• Synthesis and biological evaluation of the superagonist [N alpha-chlorotriazinylaminofluorescein-Ser1,Nle4,D-Phe7]-al pha-MSH.

  1985cited by this paper
• Prolonged stimulation of S91 melanoma tyrosinase by [Nle4, D-Phe7]-substituted alpha-melanotropins.

  1985cited by this paper
• Possible bioactive conformations of alpha-melanotropin.

  1984cited by this paper
• Deprotection of Nin-formyl tryptophan using 1,2-ethanedithiol in liquid hydrogen fluoride. Deformylation upon HF treatment of Merrifield peptidyl-resins.

  1982cited by this paper
• Structure-activity relationships of peptides derived from ACTH, beta-LPH and MSH with regard to avoidance behavior in rats.

  1982cited by this paper
• Comparative biological activities of highly potent active-site analogues of alpha-melanotropin.

  1982cited by this paper
• Calcium-dependent prolonged effects on melanophores of [4-norleucine, 7-D-phenylalanine]-alpha-melanotropin.

  1981cited by this paper
• 4-Norleucine, 7-D-phenylalanine-alpha-melanocyte-stimulating hormone: a highly potent alpha-melanotropin with ultralong biological activity.

  1980cited by this paper
• Synthesis of alpha- and beta-melanocyte stimulating hormones.

  1980cited by this paper
• Synthesis and structure-function studies of melanocyte stimulating hormone analogues modified in the 2 and 4(7) positions: comparison of activities on frog skin melanophores and melanoma adenylate cyclase.

  1980cited by this paper
• Melanotropin–daunomycin conjugate shows receptor-mediated cytotoxicity in cultured murine melanoma cells

  1977cited by this paper
• Evidence against mass action direct feedback control of melanophore-stimulating hormone (MSH) release.

  1974cited by this paper
• Solid-phase synthesis of (2-isoleucine, 4-leucine) oxytocin and (2-phenylalanine, 4-leucine) oxytocin and some their pharmacological properties.

  1973cited by this paper
• Evidence for separate receptors for melanophore stimulating hormone and catecholamine regulation of cyclic AMP in the control of melanophore responses

  1970cited by this paper
• Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides.

  1970cited by this paper
• In vitro bioassay for the melanocyte stimulating hormone.

  1954cited by this paper

• Peptide-Based Strategies for Targeted Tumor Treatment and Imaging

  2021cites this paper
• The melanocortin pathway and energy homeostasis: From discovery to obesity therapy

  2021cites this paper
• The melanocortin pathway and control of appetite-progress and therapeutic implications.

  2019cites this paper
• Replacement of Arg with Nle and modified D-Phe in the core sequence of MSHs, Ac-His-D-Phe-Arg-Trp-NH2, leads to hMC1R selectivity and pigmentation.

  2018cites this paper
• Systematic Backbone Conformational Constraints on a Cyclic Melanotropin Ligand Leads to Highly Selective Ligands for Multiple Melanocortin Receptors.

  2015cites this paper
• Temporal cAMP Signaling Selectivity by Natural and Synthetic MC4R Agonists.

  2015cites this paper
• Structure-activity relationships of peptides incorporating a bioactive reverse-turn heterocycle at the melanocortin receptors: identification of a 5800-fold mouse melanocortin-3 receptor (mMC3R) selective antagonist/partial agonist versus the mouse melanocortin-4 receptor (mMC4R).

  2013cites this paper
• Conformational study on cyclic melanocortin ligands and new insight into their binding mode at the MC4 receptor.

  2011cites this paper
• Structure-activity relationships (SAR) of melanocortin and agouti-related (AGRP) peptides.

  2010cites this paper
• Interactions of the Melanocortin-4 Receptor with the Peptide Agonist NDP-MSH

  2010cites this paper
• Beta-turn secondary structure and melanocortin ligands.

  2009cites this paper
• Rational approach to design of melanocortin ligands and receptor chimeras

  2008cites this paper
• The first preparative solution phase synthesis of melanotan II

  2008cites this paper
• Structure-activity relationships of beta-MSH derived melanocortin-4 receptor peptide agonists.

  2007cites this paper
• The melanocortin circuit in obese and lean strains of chicks.

  2006cites this paper
• Overview of endogenous and synthetic melanocortin peptides.

  2006cites this paper
• Identification of novel hexapeptide agonists at the Xenopus laevis melanophore melanocortin receptor.

  2005cites this paper
• Novel 3D pharmacophore of alpha-MSH/gamma-MSH hybrids leads to selective human MC1R and MC3R analogues.

  2005cites this paper
• Isolation and characterization of antagonist and agonist peptides to the human melanocortin 1 receptor.

  2005cites this paper
• Melanocortin ligands: 30 years of structure–activity relationship (SAR) studies

  2004cites this paper
• Progress in the development of melanocortin receptor selective ligands.

  2004cites this paper
• Facile synthesis of Nalpha-protected-L-alpha,gamma-diaminobutyric acids mediated by polymer-supported hypervalent iodine reagent in water.

  2004cites this paper
• Design of novel chimeric melanotropin-deltorphin analogues. Discovery of the first potent human melanocortin 1 receptor antagonist.

  2003cites this paper
• Characterization of aliphatic, cyclic, and aromatic N-terminally "capped" His-D-Phe-Arg-Trp-NH2 tetrapeptides at the melanocortin receptors.

  2003cites this paper
• Development of potent truncated glucagon antagonists.

  2001cites this paper
• Fluorescence study of conformational properties of melanotropins labeled with aminobenzoic acid.

  2001cites this paper
• Melanocortins and the brain: from effects via receptors to drug targets.

  2000cites this paper
• Tryptophan fluorescence studies of melanotropins in the amphiphile-water interface of reversed micelles

  2000cites this paper
• Conformation of the Core Sequence in Melanocortin Peptides Directs Selectivity for the Melanocortin MC3 and MC4 Receptors*

  1999cites this paper
• Molecular dynamics simulation of α-melanocyte stimulating hormone in a water-membrane model interface

  1999cites this paper
• NMR and quenched molecular dynamics studies of superpotent linear and cyclic alpha-melanotropins.

  1998cites this paper
• Binding and biological activity of C-terminally modified melanocortin peptides: a comparison between their actions at rodent MC1 and MC3 receptors.

  1997cites this paper
• Melanotropic Peptides for Therapeutic and Cosmetic Tanning of the Skin

  1993cites this paper
• Design, Synthesis, and Conformation of Superpotent and Prolonged Acting Melanotropins a

  1993cites this paper
• Biological activities of melanotropic peptide fatty acid conjugates.

  1991cites this paper
• Design, synthesis, and biological activities of a potent and selective alpha-melanotropin antagonist.

  1990cites this paper
• Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations.

  1990cites this paper
• Potent and prolonged acting cyclic lactam analogues of alpha-melanotropin: design based on molecular dynamics.

  1989cites this paper
• Linear and cyclic alpha-melanotropin [4-10]-fragment analogues that exhibit superpotency and residual activity.

  1989cites this paper